Literature DB >> 12642016

The role of angiotensin II in regulating vascular structural and functional changes in hypertension.

Rhian M Touyz1.   

Abstract

A major hemodynamic abnormality in hypertension is increased peripheral resistance due to changes in vascular structure and function. Structural changes include reduced lumen diameter and arterial wall thickening. Functional changes include increased vasoconstriction and/or decreased vasodilation. These processes are influenced by many humoral factors, of which angiotensin II (Ang II) seems to be critical. At the cellular level, Ang II stimulates vascular smooth muscle cell growth, increases collagen deposition, induces inflammation, increases contractility, and decreases dilation. Molecular mechanisms associated with these changes in hypertension include upregulation of many signaling pathways, including tyrosine kinases, mitogen-activated protein kinases, RhoA/Rho kinase, and increased generation of reactive oxygen species. This review focuses on the role of Ang II in vascular functional and structural changes of small arteries in hypertension. In addition, cellular processes whereby Ang II influences vessels in hypertension are discussed. Finally, novel concepts related to signaling pathways by which Ang II regulates vascular smooth muscle cells in hypertension are introduced.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642016     DOI: 10.1007/s11906-003-0073-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  82 in total

Review 1.  Vascular smooth muscle growth: autocrine growth mechanisms.

Authors:  B C Berk
Journal:  Physiol Rev       Date:  2001-07       Impact factor: 37.312

2.  Need to test the arterial inflammation hypothesis.

Authors:  Deepak L Bhatt; Eric J Topol
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor.

Authors:  E L Schiffrin
Journal:  J Cardiovasc Pharmacol       Date:  1996       Impact factor: 3.105

5.  Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats.

Authors:  N Varo; M J Iraburu; M Varela; B López; J C Etayo; J Díez
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

Review 6.  Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors.

Authors:  Y Saito; B C Berk
Journal:  J Mol Cell Cardiol       Date:  2001-01       Impact factor: 5.000

Review 7.  Pathophysiology of essential hypertension: role of the pump, the vessel, and the kidney.

Authors:  Ashley E Cain; Raouf A Khalil
Journal:  Semin Nephrol       Date:  2002-01       Impact factor: 5.299

8.  Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats.

Authors:  Yasushi Mukai; Hiroaki Shimokawa; Midoriko Higashi; Keiko Morikawa; Tetsuya Matoba; Junko Hiroki; Ikuko Kunihiro; Hassan M A Talukder; Akira Takeshita
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

9.  Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients.

Authors:  E L Schiffrin; L Y Deng
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

10.  Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.

Authors:  Gian Paolo Rossi; Martina Cavallin; Anna S Belloni; Giuseppina Mazzocchi; Gastone G Nussdorfer; Achille C Pessina; Saverio Sartore
Journal:  Cardiovasc Res       Date:  2002-07       Impact factor: 10.787

View more
  32 in total

Review 1.  Mechanisms of the Anti-Ischemic Effect of Angiotensin II AT( 1 ) Receptor Antagonists in the Brain.

Authors:  Juan M Saavedra; Julius Benicky; Jin Zhou
Journal:  Cell Mol Neurobiol       Date:  2006-04-25       Impact factor: 5.046

2.  Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension.

Authors:  L Gabriel Navar
Journal:  J Appl Physiol (1985)       Date:  2010-12

Review 3.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

4.  Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.

Authors:  Cuneyt K Buharalioglu; Chi Young Song; Fariborz A Yaghini; Hafiz U B Ghafoor; Mustafa Motiwala; Tusita Adris; Anne M Estes; Kafait U Malik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-03       Impact factor: 4.733

Review 5.  The roles of integrins in mediating the effects of mechanical force and growth factors on blood vessels in hypertension.

Authors:  Jun-Tzu Chao; Michael J Davis
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

Review 6.  Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension.

Authors:  Verdiana Ravarotto; Elisa Pagnin; Antonio Fragasso; Giuseppe Maiolino; Lorenzo A Calò
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-03-11

7.  Overexpression of SIRT1 in vascular smooth muscle cells attenuates angiotensin II-induced vascular remodeling and hypertension in mice.

Authors:  Peng Gao; Ting-Ting Xu; Jie Lu; Li Li; Jing Xu; De-Long Hao; Hou-Zao Chen; De-Pei Liu
Journal:  J Mol Med (Berl)       Date:  2013-12-19       Impact factor: 4.599

8.  Vasopressor hormones in shock-noradrenaline, vasopressin or angiotensin II: which one will make the race?

Authors:  Martin W Dünser; Jens Meier
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

9.  Rutaecarpine inhibits angiotensin II-induced proliferation in rat vascular smooth muscle cells.

Authors:  Yan-ju Li; Feng Zhang; Qi-hai Gong; Qin Wu; Li-mei Yu; An-sheng Sun
Journal:  Chin J Integr Med       Date:  2013-06-17       Impact factor: 1.978

10.  Relationship between NOX4 level and angiotensin II signaling in Gitelman's syndrome. Implications with hypertension.

Authors:  Lorenzo A Calò; Carmine Savoia; Paul A Davis; Elisa Pagnin; Verdiana Ravarotto; Giuseppe Maiolino
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.